Iovance Biotherapeutics, Inc.: shareholders and insiders

IOVANASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$6.90

November 20, 2026Market cap $3.2B

What Ploutos Investor adds for Iovance Biotherapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 13 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Insiders and their shares

Purchases and sales by officers and directors from Nov 22, 2025 to Nov 13, 2026, from their own Form 4 filings.

25 Form 4s

Bought on the market

–

nobody

Sold on the market

–

nobody

From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

No sales in the period.

No trades under these filters.

From the Form 4s insiders file with the SEC within two business days of each trade.

Insiders and their shares

Every buy and sale by IOVA's officers and directors from 2011 up to November 21, 2025, 15 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

1 Holders over 5%Nov 10, 2026 Latest filing
  • BlackRock, Inc.
    Share of class7.50%
Fell to 5% or less (3)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • State Street4.80%Nov 10, 202613G
  • The Vanguard Group0.00%Mar 27, 202613G/A
  • Perceptive Advisors LLC3.80%May 15, 202513G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • D.E. Shaw
    In the quarter+328%
  • Bridgewater (Dalio)
    In the quarter
  • Point72 (Cohen)
    In the quarter
  • Millennium Mgmt (Englander)
    In the quarter-78%
  • AQR Capital
    In the quarter-3.3%
  • Citadel Advisors (Griffin)
    In the quarter-44%
  • Renaissance Technologies
    In the quarter

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 12.7% of its shares outstanding were held short, -9.1% since the report before.

Shares held short
58.93M
12.7%
Since the report before64.83M on Sep 30, 2026
-9.1%
4.4
13.31M
More days to cover thanof 4,578 US-listed companies with enough volume
54%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 38.86M
  • Nov 15, 2023: Shares held short 35.59M
  • Nov 30, 2023: Shares held short 34.59M
  • Dec 15, 2023: Shares held short 35.28M
  • Dec 29, 2023: Shares held short 36.41M
  • Jan 12, 2024: Shares held short 43.27M
  • Jan 31, 2024: Shares held short 41.97M
  • Feb 15, 2024: Shares held short 42.98M
  • Feb 29, 2024: Shares held short 46.71M
  • Mar 15, 2024: Shares held short 47.43M
  • Mar 28, 2024: Shares held short 46.38M
  • Apr 15, 2024: Shares held short 48.98M
  • Apr 30, 2024: Shares held short 50.06M
  • May 15, 2024: Shares held short 51.21M
  • May 31, 2024: Shares held short 49.96M
  • Jun 14, 2024: Shares held short 54.63M
  • Jun 28, 2024: Shares held short 56.42M
  • Jul 15, 2024: Shares held short 58.94M
  • Jul 31, 2024: Shares held short 61.32M
  • Aug 15, 2024: Shares held short 59.33M
  • Aug 30, 2024: Shares held short 57.69M
  • Sep 13, 2024: Shares held short 60.29M
  • Sep 30, 2024: Shares held short 59.95M
  • Oct 15, 2024: Shares held short 60.34M
  • Oct 31, 2024: Shares held short 59.73M
  • Nov 15, 2024: Shares held short 53.99M
  • Nov 29, 2024: Shares held short 56.92M
  • Dec 13, 2024: Shares held short 59.33M
  • Dec 31, 2024: Shares held short 61.31M
  • Jan 15, 2025: Shares held short 61.98M
  • Jan 31, 2025: Shares held short 63.91M
  • Feb 14, 2025: Shares held short 63.60M
  • Feb 28, 2025: Shares held short 59.59M
  • Mar 14, 2025: Shares held short 67.30M
  • Mar 31, 2025: Shares held short 75.19M
  • Apr 15, 2025: Shares held short 71.37M
  • Apr 30, 2025: Shares held short 74.57M
  • May 15, 2025: Shares held short 77.02M
  • May 30, 2025: Shares held short 86.36M
  • Jun 13, 2025: Shares held short 90.96M
  • Jun 30, 2025: Shares held short 96.78M
  • Jul 15, 2025: Shares held short 98.63M
  • Jul 31, 2025: Shares held short 67.71M
  • Aug 15, 2025: Shares held short 71.36M
  • Aug 29, 2025: Shares held short 71.32M
  • Sep 15, 2025: Shares held short 65.70M
  • Sep 30, 2025: Shares held short 72.97M
  • Oct 15, 2025: Shares held short 83.61M
  • Oct 31, 2025: Shares held short 95.42M
  • Nov 14, 2025: Shares held short 116M
  • Nov 28, 2025: Shares held short 119M
  • Dec 15, 2025: Shares held short 120M
  • Dec 31, 2025: Shares held short 119M
  • Jan 15, 2026: Shares held short 117M
  • Jan 30, 2026: Shares held short 105M
  • Feb 13, 2026: Shares held short 131M
  • Feb 27, 2026: Shares held short 131M
  • Mar 13, 2026: Shares held short 115M
  • Mar 31, 2026: Shares held short 111M
  • Apr 15, 2026: Shares held short 109M
  • Apr 30, 2026: Shares held short 115M
  • May 15, 2026: Shares held short 107M
  • May 29, 2026: Shares held short 104M
  • Jun 15, 2026: Shares held short 103M
  • Jun 30, 2026: Shares held short 101M
  • Jul 15, 2026: Shares held short 99.89M
  • Jul 31, 2026: Shares held short 99.98M
  • Aug 14, 2026: Shares held short 103M
  • Aug 31, 2026: Shares held short 88.14M
  • Sep 15, 2026: Shares held short 87.13M
  • Sep 30, 2026: Shares held short 64.83M
  • Oct 15, 2026: Shares held short 58.93M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading41.0% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 41.0% of the shares in the reported trades were short sales, against 36.3% in the 14 before.

Last 14 sessionsNov 3, 2026 – Nov 20, 2026
41.0%
The 14 beforeOct 14, 2026 – Nov 2, 2026
36.3%
Change
+4.7 pts
Short sales a dayon average, of 5.33M shares
2.19M
More than atof 3,666 US-listed companies, same days
22%
Median of alleight in ten from 34.4% to 63.9%
50.5%
  • Oct 14, 2026: Short sales 39.7%
  • Oct 15, 2026: Short sales 31.9%
  • Oct 16, 2026: Short sales 48%
  • Oct 19, 2026: Short sales 38.8%
  • Oct 20, 2026: Short sales 38.7%
  • Oct 21, 2026: Short sales 40.1%
  • Oct 22, 2026: Short sales 39.1%
  • Oct 23, 2026: Short sales 41.5%
  • Oct 26, 2026: Short sales 35.4%
  • Oct 27, 2026: Short sales 35.1%
  • Oct 28, 2026: Short sales 39.5%
  • Oct 29, 2026: Short sales 35.1%
  • Oct 30, 2026: Short sales 30.9%
  • Nov 2, 2026: Short sales 31.1%
  • Nov 3, 2026: Short sales 38.1%
  • Nov 4, 2026: Short sales 49.1%
  • Nov 5, 2026: Short sales 43.6%
  • Nov 6, 2026: Short sales 38.3%
  • Nov 9, 2026: Short sales 39.6%
  • Nov 10, 2026: Short sales 45.9%
  • Nov 11, 2026: Short sales 45.1%
  • Nov 12, 2026: Short sales 47%
  • Nov 13, 2026: Short sales 35.4%
  • Nov 16, 2026: Short sales 44.4%
  • Nov 17, 2026: Short sales 35.4%
  • Nov 18, 2026: Short sales 33.8%
  • Nov 19, 2026: Short sales 39.5%
  • Nov 20, 2026: Short sales 31.6%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

29.79M Insiders' shares7.23% Of the company
  • Wayne P. RothbaumDirector
    Directly–
  • Frederick G VogtInterim CEO & General Counsel
    Directly604.1K
  • Merrill A McpeakDirector
    Directly320.2K
  • Raj K. PuriChief Regulatory Officer
    Directly256.4K
  • Daniel Gordon KirbyChief Commercial Officer
    Directly160.6K
  • Igor BilinskyChief Operating Officer
    Directly142.1K
  • Finckenstein Friedrich GrafChief Medical Officer
    Directly140.1K
  • Iain D. DukesDirector
    Directly54.0K
  • Corleen M. RocheChief Financial Officer
    Directly35.9K
  • Ryan D MaynardDirector
    Directly7,500

A lower bound: it counts only the 10 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

22 ETFs holding it0.56% The largest weight (XBI)
  • XBIState Street(R) SPDR(R) S&P(R) Biotech ETF
    Weight in the fund0.56%
  • LABUDirexion Daily S&P Biotech Bull 3X Shares
    Weight in the fund0.41%
  • IBBiShares Biotechnology ETF
    Weight in the fund0.13%
  • IWNiShares Russell 2000 Value ETF
    Weight in the fund0.11%
  • VTWOVanguard Russell 2000 Index Fund
    Weight in the fund0.10%
  • FESMFidelity Enhanced Small Cap Core ETF
    Weight in the fund0.09%
  • SCHASchwab U.S. Small-Cap ETF
    Weight in the fund0.06%
  • IWMiShares Russell 2000 ETF
    Weight in the fund0.05%
  • VHTVanguard Health Care Index Fund
    Weight in the fund0.04%
  • DFASDimensional U.S. Small Cap ETF
    Weight in the fund0.03%

22 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

292 Managers, Q2 2026$1.2B Value of their positions
  • Q3 2025: Managers 253
  • Q4 2025: Managers 263
  • Q1 2026: Managers 288
  • Q2 2026: Managers 292

Institutional investors by quarter

The fund managers holding IOVA, quarter by quarter, from Q2 2017 to Q2 2025, 33 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 292 managers held 287M shares, worth $1.2B. During the quarter 45 opened a position, 41 closed one, 126 added and 64 trimmed.

The largest holders, Q2 2026

  • BlackRock
    In the quarter+19%
  • Mhr Fund Management
    In the quarter
  • State Street
    In the quarter+40%
  • Two Sigma Investments
    In the quarter+39%
  • Vanguard Capital Management
    In the quarter+9.5%
  • Vanguard Portfolio Management
    In the quarter+23%
  • Geode Capital Management
    In the quarter+20%
  • Millennium Mgmt (Englander)
    In the quarter-9.4%
  • Dimensional Fund Advisors
    In the quarter+144%
  • Palo Alto Investors
    In the quarter-17%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do Iovance Biotherapeutics's filings show?

Who buys and sells is one part of Iovance Biotherapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about IOVA's shareholders

Didn't find what you were looking for?

Ask us
Have IOVA's insiders bought or sold?

From Jun 3, 2026 to Nov 13, 2026 Iovance Biotherapeutics's insiders reported no purchase or sale of shares on the market.

Which well-known managers hold IOVA?

7 of the managers we track held the shares on Sep 30, 2026. The largest position was D.E. Shaw's, worth $136M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.